Expert Point of View: Charles E. Geyer, Jr, MD, FACP

Get Permission

Charles E. Geyer, Jr, MD, FACP

Although the study clearly showed statistically significant differences, discussant Charles E. Geyer, Jr, MD, FACP, Associate Director of Clinical Research at the Massey Cancer Center in Richmond, Virginia, indicated that it’s unclear whether these are “clinically relevant differences,” adding that, overall, there were more similarities than differences between the geriatric and younger populations.

“The most interesting data for me were the high percentage of PD-1 and PD-L1 markers in staining,” said Dr. Geyer. “I think these are much higher numbers than what we’ve seen reported, particularly in the hormone receptor–positive/HER2-negative patients.”

“I would differ with Dr. Pohlmann’s conclusions that the study provides relevant information for the design of clinical trials focusing on geriatric patient population,” Dr. Geyer remarked. “Rather, the data suggest the focus needs to be on inclusion of geriatric patients in our targeted therapy trials. I think it would be a mistake to peel these patients off and attempt to evaluate them in separate studies.” ■

Disclosure: Dr. Geyer reported no potential conflicts of interest.


Related Articles

Tumor Profiling of Breast Tumors in Older Patients Reveals Differences From Those of Younger Patients

Using multiplatform profiling, researchers have identified potentially targetable biomarker aberrations in a large cohort of geriatric breast tumors.1 According to the study, presented at the 2015 Breast Cancer Symposium, these data may help researchers to design clinical trials focusing on...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.